



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

February 11, 2020

National Stock Exchange of India Ltd.
Exchange Plaza Block G, C 1,
Bandra Kurla Complex, Bandra East,
Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: US FDA approval of New Solid Oral dosage forms formulations manufacturing facility at Panoli, Gujarat

We wish to inform you that the Company is in receipt of the Establishment Inspection Report (EIR) from the US FDA for the Company's newly set up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat. The US FDA issues an EIR to the Company when an inspection is satisfactorily "closed". The said inspection was carried out from 24th June to 28th June 2019. At the end of the inspection, "No Objectionable Observation" were found and no Form 483 was issued.

This new facility known as (T20) has already been approved by the other regulatory authorities like EU, TGA-Australia, Saphra-South Africa. This is an another facility in addition to one already approved by US FDA.

The new facility will augment the Company's manufacturing capacity for regulated markets like USA, EU, Australia and South Africa.

We request you to take the above announcement on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Limited

S.B. Mody
Whole time Director (Marketing)

📍 **Registered Office:**

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500

☎ +91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

🌐 www.jbcpl.com

CIN: L24390MH1976PLC019380